I-Mab(IMAB) - 2025 Q2 - Quarterly Report

Exhibit 99.1 I-Mab Reports Second Quarter 2025 Financial Results and Provides Business Update ROCKVILLE, MD, August 20, 2025 – I-Mab (NASDAQ: IMAB) (I-Mab or the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced financial results for the three and six months ended June 30, 2025, and highlighted recent pipeline progress and business updates. "The first half of 2025 has been transformative for I-Mab," sai ...